Axonics (Nasdaq:AXNX) announced that its stockholders voted to adopt its $3.7 billion merger agreement with Boston Scientific . Boston Scientific announced its intent to buy Axonics on Jan. 8. Irvine, California-based Axonics develops neuromodulation systems for treating urinary and bowel dysfunction. Its fourth-generation R20 rechargeable sacral neuromodulation (SNM) system received FDA approval around a year ago. […]
Axonics
PTAB upholds two Medtronic patents in spat with Axonics, could go to jury trial
Medtronic announced today that the U.S. Patent and Trademark Office upheld many of its claims around two of its patents in its battle with Axonics (Nasdaq:AXNX). The office’s Patent Trial and Appeal Board (PTAB) affirmed the validity of many of the claims in two of Medtronic’s patents in the latest development in a long-running spat […]
Axonics wins CE mark for 4th-gen rechargeable sacral neuromod system
Axonics (Nasdaq:AXNX) announced today that it received CE mark approval for its R20 rechargeable sacral neuromodulation (SNM) system. The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. Axonics won FDA approval for this generation of the R20 in January 2023. The R20 neurostimulator uses the same small 5cc form factor […]
FTC reportedly may scrutinize Boston Scientific’s Axonics deal
Bloomberg reports that the U.S. Federal Trade Commission (FTC) may look into the $3.7 billion acquisition of Axonics (Nasdaq:AXNX) by Boston Scientific . A new Axonics regulatory filing with the SEC discloses that the companies refiled their Hart Scott Rodino (HSR) Act notification to the FTC on March 4 — a move that companies sometimes […]
Medtronic asks ITC to stop Axonics’ sales of neuromod devices
Medtronic today announced that it filed a complaint to the U.S. International Trade Commission (ITC) to block the sales of certain Axonics (Nasdaq:AXNX) devices. The complaint to the ITC runs parallel to action in the U.S. District Court for the District of Delaware. Medtronic wants to block Axonics from “improperly importing and selling products that infringe […]
Boston Scientific to acquire Axonics for $3.7B
Boston Scientific announced today that it agreed to acquire Axonics (Nasdaq:AXNX) in a deal worth approximately $3.7 billion. Shares of AXNX skyrocketed before the market opened today, rising 21.1% to $69.72 apiece. Shares of BSX stayed even. Marlborough, Massachusetts-based Boston Scientific priced the acquisition at $71 in cash per share. It amounts to an equity […]
Artificial heart maker BiVacor names Axonics CEO as chair of its board
BiVacor announced today that it appointed Axonics CEO Raymond W. Cohen as the new chair of its board of directors. Cohen serves as CEO and as a member of the board at Axonics, which develops sacral neuromodulation technologies. He originally founded Axonics in 2013 and took the Irvine, California-based company public in October 2018. The long-time […]
Axonics CFO to retire, successor promoted from within
Axonics (Nasdaq:AXNX) announced today that Dan Dearen, president and CFO, is retiring from his position at the neuromodulation company. Irvine, California-based Axonics tabbed Kari Keese, VP of finance and accounting, to succeed Dearen. Her appointment goes into effect on Oct. 2. “On behalf of the Axonics team and the board of directors, I want to […]
Axonics acquires tech to expedite placement of implantable leads in sacral neuromod
Axonics (Nasdaq:AXNX) today announced it acquired lead placement technology from Radian to speed up the placement of implantable leads for sacral neuromodulation. Axonics acquired the assets of Radian from Intermed Labs for an undisclosed amount. The company expects the product to receive FDA clearance and be available on a commercial basis in mid-2024. The acquired technology […]
New medtech to watch for in 2023: boosting health outcomes
As earnings season is upon us, we’re receiving a clearer view of what new medtech could be launching this year in the medical device space. Companies still feel hamstrung by macroeconomic pressures, supply chain issues and more. However, many pointed out that 2023 has plenty to look forward to. Several quarterly reports and earnings calls […]
FDA approves fourth-gen rechargeable sacral neuromod tech from Axonics
Axonics (Nasdaq:AXNX) announced today that the FDA approved its fourth-generation R20 rechargeable sacral neuromodulation system. The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. The approval indicates the Axonics R20 for a functional life in the body of at least 20 years. It also reduces the frequency with which a […]